FindMyKOL

Lee Hartner, MD

Basic profile

Abramson Cancer Center

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionPhiladelphia, PA · NortheastSpecialtyHematology / OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Lee Hartner is an Oncology physician affiliated with Abramson Cancer Center. OpenAlex indexes 41 publications with 1,064 citations (h-index 15).

Overview

Scholarship

indexed output and impact (OpenAlex)
41publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

1,064citations

Citations across these publications.

15h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • PTC Therapeutics
    Program year20251 paymentResearch
    $8,917
  • SpringWorks Therapeutics
    Program year20251 paymentResearch
    $4,845
  • AstraZeneca Pharmaceuticals LP
    Program year20251 payment
    $43
All 13 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    46.4%
    Opioid Agonist19.9%
    Oxycodone Hcl76%Morphine Sulfate Er24%
    Part D<11 patients
    Gabapentinoids15.8%
    Gabapentin100%
    Part D≥17 patients

    + 2 more classes in this area

  • Blood & clotting

    16.2%
    Factor Xa inhibitor11.7%
    Eliquis65%Xarelto35%
    Part D<11 patients
    Vitamin K antagonist4.5%
    Warfarin Sodium100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    15.8%
    Serotonin-3 Receptor Antagonist8.6%
    Ondansetron Hcl100%
    Part D≥15 patients
    Corticosteroid7.2%
    Prednisone100%
    Part D<11 patients
Where care is delivered (Part B)5.6% facility · 94.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”